Last updated: February 20, 2026
What is NDC 00088-2500?
NDC 00088-2500 corresponds to Rituximab, a monoclonal antibody used primarily for treatment of CD20-positive B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, and other autoimmune diseases. It is marketed under brand names such as Rituxan by Roche.
Market Overview
Market Size
- The global Rituximab market was valued at approximately USD 6.9 billion in 2022.
- Post-2020, the market expanded due to increased adoption for autoimmune conditions and expanding indications.
Key Market Drivers
- Increasing prevalence of non-Hodgkin lymphoma and autoimmune diseases.
- Growing adoption of biosimilar versions, reducing costs.
- Higher diagnosis rates, notably in North America and Europe.
- Expanded approval for new indications, including COVID-19-related complications.
Competition Landscape
- Main branded product: Rituxan (Roche)
- Biosimilars: Multiple FDA-approved biosimilar versions introduced since 2017, including:
- Truxima (Miltenyi Biotec)
- Ruxience (Pfizer)
- Riazzo (Celltrion)
Regional Market Shares
| Region |
Market Share (2022) |
CAGR (2023-2028) |
| North America |
55% |
5.6% |
| Europe |
28% |
4.8% |
| Asia-Pacific |
10% |
7.2% |
| ROW (Rest of World) |
7% |
6.5% |
Key Trends
- Biosimilar penetration is accelerating; over 60% of Rituximab sales in Europe are biosimilars (IQVIA, 2022).
- Oncology indications drive the majority of revenue, with autoimmune uses growing faster.
- New formulations and delivery methods may enhance patient adherence.
Price Trends and Projections
Current Pricing
| Product Type |
List Price (per vial USD) |
Discounted Price (approximate, USD) |
| Reference brand (Rituxan) |
3,200 |
2,600 |
| Biosimilars (average) |
2,200 |
1,800 |
Price Drivers
- Biosimilar competition has decreased average prices by approximately 30-35% since 2017.
- Reimbursement policies and healthcare budgets impact actual transaction prices.
- Manufacturing costs for biosimilars continue to decline with increased scale.
Price Projections (2023-2028)
- Biosimilar prices are expected to decrease further by 5-10% annually, driven by increased competition and manufacturing efficiencies.
- Originator price stabilization expected due to limited supply constraints; potential for slight decline in list price to maintain market share.
- Average per-vial prices forecasted as follows:
- 2023: USD 1,800
- 2026: USD 1,500
- 2028: USD 1,400
Impact of Policy and Market Dynamics
- US and EU reimbursement policies favor biosimilar use, encouraging price reductions.
- New indications and expanded use cases increase volume, offsetting price declines.
- Possible entry of novel therapies (e.g., BTK inhibitors, CAR T-cell therapies) could impact Rituximab’s market share and pricing.
Market Share and Revenue Projections
| Year |
Estimated Global Revenue (USD Billion) |
Estimated Biosimilar Penetration |
Notes |
| 2023 |
7.2 |
60% |
Biosimilar adoption continues to grow |
| 2025 |
7.8 |
70% |
Increased biosimilar market share |
| 2028 |
8.5 |
80% |
CAGR of ~4.8% from 2023 to 2028 due to volume growth |
Policy Impacts and Risks
- U.S. FDA initiatives on biosimilar pathways aim to increase competition.
- Reimbursement reforms could alter pricing dynamics.
- Patent litigations may delay biosimilar market entry.
Summary
- The Rituximab (NDC 00088-2500) market has stabilized with significant biosimilar adoption.
- Prices are forecasted to decline gradually, with biosimilar prices dropping more sharply.
- Market growth depends on continuation of biosimilar penetration, indication expansion, and policy environment.
Key Takeaways
- Biosimilars dominate the market, reducing prices and expanding access.
- Revenue growth remains positive due to volume increases rather than pricing.
- Price declines of about 10-15% per year are expected for biosimilar products.
- Future competition from innovative therapies may impact Rituximab’s market share.
- Regulatory policies and patent strategies will significantly influence pricing and availability.
FAQs
What factors influence Rituximab’s pricing?
Manufacturing costs, biosimilar competition, reimbursement policies, and negotiated discounts.
How do biosimilars affect Rituximab prices?
Biosimilars reduce list prices due to competition, typically by 30-35% since market entry.
Will Rituximab face competition from other therapies?
Yes, especially with the advent of targeted therapies like CAR T-cells and small molecule inhibitors.
How do regional differences impact market size?
North America accounts for more than half of revenue; Asia-Pacific shows rapid growth but lower per-unit prices.
What is the outlook for Rituximab’s market share?
Market share declines expected due to biosimilar proliferation and alternative therapies but maintained volume growth supports revenue.
References
- IQVIA. (2022). Global Biosimilar Market Overview.
- EvaluatePharma. (2023). Biosimilar Rituximab Market Forecast.
- FDA. (2022). Biosimilar Biological Product Approval.
- European Medicines Agency. (2022). Biosimilar Medicinal Products. Regulatory Requirements.
